Cleo Diagnostics’ Post

September is Gynaecological Cancer Awarenesss Month. Remember that, No screening test exists today for #OvarianCancer. The 5-year survival rate for Ovarian Cancer is just 49%, compare that to Breast Cancer (92%), Uterine Cancer (84%), and Cervical Cancer (74%). Accurate and early detection of Ovarian Cancer could significantly increase survival. Cleo Diagnostics is leading the way to early diagnosis with its simple and accurate blood test. #GynaecologicalCancerAwarenessMonth #CleoDX #ovarian #cancer #medtech #womenshealth ASX.COV #invest ___________________________

To view or add a comment, sign in

Explore topics